RadNet, Inc. (RDNT)
NEGATIVEFundamental
35
Kurs
$76.22
Marktkapitalisierung
$5.92B
Teil 1 · Was das Unternehmen wert ist
Übersicht
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$2.27B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$-21M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
-
Gesamtes Eigenkapital
$1.09B
Gesamtverbindlichkeiten
$2.40B
Current Ratio
1.48
Zinsdeckungsgrad
0.99
Schulden/EBITDA
10.20
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$52.45
Aktueller Kurs
$76.22
Sicherheitsmarge
-45.3%
Innerer-Wert-Spanne
$34.09 - $70.81
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
-
ROE
-1.7%
P/B-Verhältnis
5.36
P/FCF
-
Bruttomarge
-
ROIC
1.6%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
1.6%
WACC
9.7%
ROIC − WACC
-8.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (6)
- Price CAGR 28.12%
- Debt/Equity ratio
- Current Ratio
- Revenue Growth 5Y 13.7%
- Analyst Consensus 93% Buy
- Earnings Surprise avg 13.4%
Nicht bestanden (13)
- EPS shows upward trend
- ROIC 1.6%
- P/B Ratio 5.36
- Operating Margin 3.1%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -1.4%
- Share Dilution 6.8%
- Net Margin Trend -0.9% vs -0.8%
- Piotroski F-Score 3/9
Nicht verfügbar (8)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Neue Aktien werden ausgegeben, Eigentum wird verwässert
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Dr. Howard G. Berger M.D. | Chairman, President & CEO | 79 |
| Mr. Mark D. Stolper | Executive VP & CFO | 54 |
| Mr. Mital Patel | Executive VP & COO | 39 |
| Mr. Norman R. Hames | President & CEO of Western Operations | 69 |
| Mr. Stephen M. Forthuber | President & CEO of Eastern Operations | 64 |
| Dr. Alma Gregory Sorensen M.D. | Executive VP, Chief Strategy Officer & Director | 63 |
| Ms. Susan Hollabaugh | Chief Information Officer | - |
| Mr. David Jeffrey Katz Esq. | Executive VP, Chief Legal Officer & Corporate Secretary | 61 |
| Mr. David Manheim | Senior VP & Chief Compliance Officer | - |
| Mr. Michael M. Murdock | Executive Vice President of Mergers & Acquisitions | 70 |
Prüfungsrisiko
8
Vorstandsrisiko
8
Vergütungsrisiko
7
Aktionärsrechterisiko
2
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for RDNT, sourced from Markets Gazette.
- 3/2/2026NEUTRALRadNet (RDNT) Q4 2025 Earnings Call Transcript
The transcript for RadNet Inc.'s (RDNT) Q4 2025 earnings call is now available to investors. While access to such documents is crucial for understanding the company's financial performance and future outlook, the current lack of specific content details prevents an immediate assessment of market impact. Analysts and investors are awaiting a review of key data, management statements, and projections to evaluate RadNet's operational and strategic health. Earnings calls are pivotal moments for grasping growth trends, profit margins, and any potential challenges the company might face in the diagnostic imaging services sector. Without the content, the signal remains neutral, pending further insights.
- 3/2/2026NEUTRALRadNet Earnings Review: Q4 Summary
Markets Gazette notes the announcement of RadNet's Q4 earnings review. While the title suggests an upcoming analysis of the company's financial performance, the provided article lacks specific details regarding the results, such as revenue figures, earnings per share, or future projections. This absence of concrete data prevents investors from assessing RadNet's current financial health or anticipating potential market movements. Traders are eagerly awaiting further information to formulate informed investment strategies.
via Markets Gazette